{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:15:08Z","timestamp":1793488508442,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012754","name":"Horizon Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012754","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.rdc.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T19:06:43Z","timestamp":1569524803000},"page":"549-567","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treat to Target"],"prefix":"10.1016","volume":"45","author":[{"given":"Dario","family":"Camellino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.rdc.2019.07.005_bib1","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A\u00a0randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/dom.12129","article-title":"Treat-to-target trials: uses, interpretation and review of concepts","volume":"16","author":"Garber","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib3","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2337\/dc17-2224","article-title":"Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: report of a randomized study","volume":"41","author":"Itoh","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib4","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/2047487314567001","article-title":"Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk","volume":"23","author":"M\u00fcller-Wieland","year":"2016","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.rdc.2019.07.005_bib5","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib7","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/annrheumdis-2016-209467","article-title":"Treat-to-target (T2T) recommendations for gout","volume":"76","author":"Kiltz","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2019.07.005_bib12","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201705020","article-title":"Polymyalgia rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.rdc.2019.07.005_bib13","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","article-title":"Polymyalgia rheumatica and giant cell arteritis: a systematic review","volume":"315","author":"Buttgereit","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib14","first-page":"506","article-title":"The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease","volume":"56","author":"Dejaco","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.semarthrit.2003.09.008","article-title":"Are polymyalgia rheumatica and giant cell arteritis the same disease?","volume":"33","author":"Cantini","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2019.07.005_bib16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","article-title":"EULAR recommendations for the management of large vessel vasculitis","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/acr.23320","article-title":"Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population","volume":"70","author":"Shbeeb","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.rdc.2015.08.009","article-title":"Glucocorticoids for management of polymyalgia rheumatica and giant cell arteritis","volume":"42","author":"Matteson","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"suppl_2","key":"10.1016\/j.rdc.2019.07.005_bib20","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1093\/rheumatology\/kex459","article-title":"Prevention of glucocorticoid morbidity in giant cell arteritis","volume":"57","author":"Buttgereit","year":"2018","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib21","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3899\/jrheum.110276","article-title":"The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis","volume":"38","author":"Merkel","year":"2011","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib22","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","article-title":"Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study","volume":"42","author":"Kermani","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MD.0000000000000033","article-title":"Relapses in patients with giant cell arteritis","volume":"93","author":"Alba","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ard.2010.133850","article-title":"Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus","volume":"70","author":"Dejaco","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","article-title":"Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR)","volume":"33","author":"Lee","year":"2013","journal-title":"Rheumatol Int"},{"issue":"15","key":"10.1016\/j.rdc.2019.07.005_bib26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.2014.11100","article-title":"The PCORI perspective on patient-centered outcomes research","volume":"312","author":"Frank","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","article-title":"Why clinical trial outcomes fail to translate into benefits for patients","volume":"18","author":"Heneghan","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.rdc.2019.07.005_bib28","doi-asserted-by":"crossref","first-page":"g7818","DOI":"10.1136\/bmj.g7818","article-title":"Patient reported outcome measures in practice","volume":"350","author":"Nelson","year":"2015","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.rdc.2019.07.005_bib29","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3899\/jrheum.161139","article-title":"OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"44","author":"Robson","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2019.07.005_bib30","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.3899\/jrheum.141144","article-title":"Update on outcome measure development for large vessel vasculitis: report from OMERACT 12","volume":"42","author":"Aydin","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3899\/jrheum.110977","article-title":"Patient-reported outcomes in polymyalgia rheumatica","volume":"39","author":"Matteson","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib32","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00296-015-3416-9","article-title":"Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review","volume":"36","author":"Huang","year":"2016","journal-title":"Rheumatol Int"},{"issue":"12","key":"10.1016\/j.rdc.2019.07.005_bib33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.3899\/jrheum.161269","article-title":"Assessment of disease activity in large-vessel vasculitis: results of an international delphi exercise","volume":"44","author":"Aydin","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2019.07.005_bib34","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3899\/jrheum.161467","article-title":"Development of a core set of outcome measures for large-vessel vasculitis: report from OMERACT 2016","volume":"44","author":"Sreih","year":"2017","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib35","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3899\/jrheum.151063","article-title":"The Birmingham vasculitis activity score as a measure of disease activity in patients with giant cell arteritis","volume":"43","author":"Kermani","year":"2016","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.005_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/rheumatology\/kex397","article-title":"Evaluation of damage in giant cell arteritis","volume":"57","author":"Kermani","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib37","doi-asserted-by":"crossref","first-page":"e017073","DOI":"10.1136\/bmjopen-2017-017073","article-title":"What is the impact of giant cell arteritis on patients\u2019 lives? A UK qualitative study","volume":"7","author":"Liddle","year":"2017","journal-title":"BMJ Open"},{"issue":"26","key":"10.1016\/j.rdc.2019.07.005_bib38","doi-asserted-by":"crossref","first-page":"e3851","DOI":"10.1097\/MD.0000000000003851","article-title":"18F-Fluorodeoxyglucose positron emission tomography and the risk of subsequent aortic complications in giant-cell arteritis","volume":"95","author":"de Boysson","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.semarthrit.2018.05.002","article-title":"Arterial lesions in giant cell arteritis: a longitudinal study","volume":"48","author":"Kermani","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/rheumatology\/39.8.883","article-title":"A\u00a0study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica","volume":"39","author":"Kalke","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib41","doi-asserted-by":"crossref","first-page":"e0126758","DOI":"10.1371\/journal.pone.0126758","article-title":"\u201cAn impediment to living life\u201d: why and how should we measure stiffness in polymyalgia rheumatica?","volume":"10","author":"Mackie","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pec.2014.12.013","article-title":"\u201cI suddenly felt I\u2019d aged\u201d: a qualitative study of patient experiences of polymyalgia rheumatica (PMR)","volume":"98","author":"Twohig","year":"2015","journal-title":"Patient Educ Couns"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0049-0172(84)90012-X","article-title":"Long-term follow-up of polymyalgia rheumatica: evidence for synovitis","volume":"13","author":"Healey","year":"1984","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.rdc.2019.07.005_bib44","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1136\/ard.2003.011379","article-title":"A\u00a0disease activity score for polymyalgia rheumatica","volume":"63","author":"Leeb","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.005_bib45","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/art.23338","article-title":"Performance of the polymyalgia rheumatica activity score for diagnosing disease flares","volume":"59","author":"Binard","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib46","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.semarthrit.2015.06.009","article-title":"Prevalence of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica","volume":"45","author":"Narv\u00e1ez","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib47","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3899\/jrheum.170455","article-title":"Development of giant cell arteritis after treating polymyalgia or peripheral arthritis: a retrospective case-control Study","volume":"45","author":"Liozon","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib48","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13075-018-1757-y","article-title":"Comorbidities in polymyalgia rheumatica: a systematic review","volume":"20","author":"Partington","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib49","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4081\/reumatismo.2018.1039","article-title":"Comorbidity in polymyalgia rheumatica","volume":"70","author":"Chatzigeorgiou","year":"2018","journal-title":"Reumatismo"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib50","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/acr.23132","article-title":"Epidemiology of polymyalgia rheumatica 2000\u20132014 and examination of incidence and survival trends over 45 years: a population-based study","volume":"69","author":"Raheel","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.005_bib51","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/art.1780390220","article-title":"Polymyalgia rheumatica in patients with a normal erythrocyte sedimentation rate","volume":"39","author":"Helfgott","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib52","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.semarthrit.2011.10.005","article-title":"Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis","volume":"41","author":"Kermani","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2019.07.005_bib53","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s10067-012-2031-3","article-title":"Systematic review of the literature and a case report informing biopsy-proven giant cell arteritis (GCA) with normal C-reactive protein","volume":"31","author":"Laria","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","article-title":"Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis","volume":"41","author":"Cid","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib55","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood-2004-07-2599","article-title":"The origins of age-related proinflammatory state","volume":"105","author":"Ferrucci","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib57","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","article-title":"Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis","volume":"48","author":"Salvarani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl","key":"10.1016\/j.rdc.2019.07.005_bib58","doi-asserted-by":"crossref","first-page":"A1120","DOI":"10.1136\/annrheumdis-2018-eular.2719","article-title":"Acute phase reactant levels and prednisone doses at disease flare in patients with giant cell arteritis: prospective data from the GiACTA trial","volume":"77","author":"Stone","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.005_bib60","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10067-018-4240-x","article-title":"Utility of serological biomarkers for giant cell arteritis in a large cohort of treatment-na\u00efve patients","volume":"38","author":"Burja","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"10","key":"10.1016\/j.rdc.2019.07.005_bib61","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1093\/rheumatology\/key158","article-title":"Immuno-monitoring reveals an extended subclinical disease activity in tocilizumab-treated giant cell arteritis","volume":"57","author":"Gloor","year":"2018","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.005_bib62","doi-asserted-by":"crossref","first-page":"e000570","DOI":"10.1136\/rmdopen-2017-000570","article-title":"Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients","volume":"3","author":"Prieto-Gonz\u00e1lez","year":"2017","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib63","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","article-title":"Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable","volume":"57","author":"Devauchelle-Pensec","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5 Suppl 39","key":"10.1016\/j.rdc.2019.07.005_bib64","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib65","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","article-title":"EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice","volume":"77","author":"Dejaco","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib66","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/rheumatology\/kem322","article-title":"Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis","volume":"47","author":"Schmidt","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/acr.22178","article-title":"Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: a consecutive case series","volume":"66","author":"Diamantopoulos","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib68","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/annrheumdis-2011-200865","article-title":"Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography","volume":"71","author":"Prieto-Gonz\u00e1lez","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"0708","key":"10.1016\/j.rdc.2019.07.005_bib69","doi-asserted-by":"crossref","first-page":"w14397","DOI":"10.4414\/smw.2017.14397","article-title":"Diagnostic value of contrast-enhanced magnetic resonance angiography in large-vessel vasculitis","volume":"147","author":"Adler","year":"2017","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"suppl_2","key":"10.1016\/j.rdc.2019.07.005_bib71","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1093\/rheumatology\/kex424","article-title":"Large-vessel giant cell arteritis: diagnosis, monitoring and management","volume":"57","author":"Koster","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib72","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrcardio.2014.80","article-title":"PET imaging of inflammation in atherosclerosis","volume":"11","author":"Tarkin","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib73","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"suppl 10","key":"10.1016\/j.rdc.2019.07.005_bib74","article-title":"Does an 18F-FDG-PET\/CT in patients with giant cell arteritis in clinical remission make sense?","volume":"70","author":"Sch\u00f6nau","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib75","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib76","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2007.082123","article-title":"MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis","volume":"67","author":"Both","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib77","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/annrheumdis-2018-213102","article-title":"Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis","volume":"77","author":"Quinn","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib78","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00259-015-3007-8","article-title":"Imaging large vessel vasculitis with fully integrated PET\/MRI: a pilot study","volume":"42","author":"Einspieler","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib79","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/ken098","article-title":"Is FDG-PET useful in the evaluation of steroid-resistant PMR patients?","volume":"47","author":"Cimmino","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.rdc.2019.07.005_bib80","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/art.11480","article-title":"Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and\/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years","volume":"48","author":"Nuenninghoff","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib81","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-122-7-199504010-00004","article-title":"Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study","volume":"122","author":"Evans","year":"1995","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.rdc.2019.07.005_bib82","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/RHU.0000000000000381","article-title":"Predictors of dissection in aortic aneurysms from giant cell arteritis","volume":"22","author":"Kermani","year":"2016","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.rdc.2019.07.005_bib83","article-title":"Development of thoracic aortic aneurysms in patients with polymyalgia rheumatica: underdiagnosed giant cell arteritis?","volume":"70","author":"Marin Zucaro","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2019.07.005_bib84","first-page":"224","article-title":"Cardiac and aortic involvement in patients with polymyalgia rheumatica: a study with echocardiography and FDG-PET\/CT","volume":"35","author":"De Lorenzi","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2019.07.005_bib85","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib86","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3899\/jrheum.150534","article-title":"Sustained remission: an unmet need in patients with giant-cell arteritis","volume":"42","author":"Cid","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2019.07.005_bib87","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib88","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.48.8.658","article-title":"Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months","volume":"48","author":"Kyle","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.rdc.2019.07.005_bib89","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2019.07.005_bib90","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","article-title":"Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial","volume":"134","author":"Jover","year":"2001","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.rdc.2019.07.005_bib91","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/art.10262","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis","volume":"46","author":"Hoffman","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2019.07.005_bib92","doi-asserted-by":"crossref","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","article-title":"Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial","volume":"146","author":"Hoffman","year":"2007","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.rdc.2019.07.005_bib93","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","article-title":"Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial","volume":"73","author":"Seror","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2019.07.005_bib94","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","article-title":"Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial","volume":"141","author":"Caporali","year":"2004","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.rdc.2019.07.005_bib95","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.rdc.2019.07.005_bib96","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","article-title":"Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study","volume":"75","author":"Devauchelle-Pensec","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X19300602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X19300602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:17:55Z","timestamp":1760181475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X19300602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0889857X19300602"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2019.07.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treat to Target","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}